NEW YORK, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”) today announced that it adjourned its annual and special meeting of shareholders (the “Meeting”) until February 12, 2026. The Meeting will now be held on February 12, 2026, at 9:00 a.m. New York Time/4:00 p.m. Cape Town time at Venture Workspace Riverlands, Office Building 4, Riverlands, 51 Gogosoa Street, Observatory, Cape Town, 7935, South Africa. The adjournment is a result of the requisi ...

Core Viewpoint - Psyence Biomedical Ltd. (NASDAQ:PBM) is currently in the spotlight due to its planned reverse stock split, which aims to increase the stock price and attract investors [1] Group 1: Reverse Stock Split - PBM initially announced a reverse stock split at a ratio of 1-for-6.25, set to take effect on January 20, 2026, but has postponed this action [2][6] - The company plans to announce a new date for the reverse stock split in the future, and until then, the stock will continue trading under the symbol "PBM" without adjustments [2] Group 2: Stock Performance - Currently, PBM's stock is priced at $0.67, with a market capitalization of approximately $478,000 [3] - The stock has experienced significant volatility, with a 52-week high of $108.59 and a low of $0.615 [3][6] - The company's price-to-earnings (P/E) ratio is 0.17, indicating that the stock is trading at a low price relative to its earnings [3] Group 3: Analyst Ratings - Analysts maintain a cautious outlook on PBM, with Weiss Ratings reaffirming a "sell (e+)" rating and the consensus rating also being "Sell" [4][6] Group 4: Trading Activity - PBM's trading volume on the Nasdaq exchange is 506,821 shares, indicating active trading [5] - The stock's 50-day moving average is $1.48, while the 200-day moving average is $3.18, reflecting a downward trend over the past year [5] - The company's beta of 0.32 suggests that the stock is less volatile compared to the overall market [5]

NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), today announced that it has decided to postpone the previously announced effective date of its reverse stock split of its issued and outstanding shares of common stock. As previously disclosed, the Company’s Board of Directors approved a reverse stock split at a ratio of 1-for-6.25, which was intended to become effective at the opening of the market on January 20, 2026. Following further in ...

NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), today announced that it has decided to postpone the previously announced effective date of its reverse stock split of its issued and outstanding shares of common stock. As previously disclosed, the Company’s Board of Directors approved a reverse stock split at a ratio of 1-for-6.25, which was intended to become effective at the opening of the market on January 20, 2026. Following further in ...

Core Viewpoint - Psyence Biomedical Ltd. has announced a 1-for-6.25 share consolidation, effective January 20, 2026, following prior approvals for share consolidations at different ratios [1][2][3]. Group 1: Share Consolidation Details - The share consolidation will combine every 6.25 issued and outstanding shares into one common share, resulting in a total of 1,022,177 common shares outstanding post-consolidation [3]. - The consolidation was approved by shareholders at a Special Meeting on April 16, 2025, allowing the Board of Directors to implement a consolidation ratio of up to 1-for-50 [1]. - The Company had previously authorized a 1-for-7.97 consolidation ratio, which was implemented on May 5, 2025 [1]. Group 2: Trading and Adjustments - Post-consolidation, the common shares will continue to trade under the symbol "PBM" on the Nasdaq Capital Market, with a new CUSIP number 74449F407 [2]. - The number of shares and the exercise price of outstanding warrants and other equity instruments will be adjusted proportionately according to their respective terms [3]. Group 3: Shareholder Impact - No fractional shares will be issued; any resulting fractions will be rounded to the nearest whole share [4]. - The consolidation affects all shareholders uniformly, with minor adjustments for fractional shares [4]. - Beneficial holders may experience delays in the reflection of the consolidation in their accounts, depending on their broker's procedures [4][5]. Group 4: Company Overview - Psyence Biomedical Ltd. is a biopharmaceutical company specializing in psychedelic-based therapeutics, focusing on nature-derived psilocybin and ibogaine-based medicines [6]. - The Company aims to address unmet mental health needs through evidence-based approaches in developing safe and effective treatments [6].

NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced that its Board of Directors (the “Board”) has approved its 2026 Financial Strategy and Capital Management Framework, which includes the authorization of a share repurchase program that the management may undertake in value generation conditions. The Board’s d ...

Core Viewpoint - Psyence Biomedical Ltd. has approved its 2026 Financial Strategy and Capital Management Framework, which includes a share repurchase program aimed at enhancing shareholder value and supporting planned clinical and regulatory milestones [1][2][3] Financial Strategy - The Board's decision was based on a comprehensive review of the Company's financial position, capital structure, and market conditions, with the goal of protecting shareholder value and preserving capital [2] - The Board believes the current market price of the Company's common shares does not reflect its underlying value, making share repurchases potentially attractive [3][4] Share Repurchase Program - The approved share repurchase program may be executed over the next six to twelve months, contingent on maintaining sufficient cash to fund clinical and regulatory milestones without impairing operational liquidity [5][6] - The Company is not obligated to repurchase shares, and the timing and amount of any repurchases will depend on market conditions and other relevant factors [6][13] Company Overview - Psyence Biomedical Ltd. is a biopharmaceutical company focused on developing nature-derived psilocybin and ibogaine therapies for mental health needs, and is the first such company to be listed on Nasdaq [7]

Core Viewpoint - Aurwest Resources Corporation has entered into a non-binding Letter of Intent with Pacific Bay Minerals Ltd to earn a 50% interest in the Weaver Gold Project over three years [1] Group 1 - Aurwest Resources Corporation is pleased to announce the agreement with Pacific Bay Minerals Ltd [1] - The agreement allows Aurwest to earn a 50% interest in Pacific Bay's 100% owned Weaver Gold Project [1] - The terms of the agreement are structured over a three-year period [1]

NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced a significant scientific and manufacturing achievement. Through its investment in PsyLabs, Psyence BioMed has become the first Nasdaq-listed company to produce GMP-compliant, high-purity ibogaine hydrochloride (Ibogaine HCl) derived from a naturally extracted ...

Core Viewpoint - Psyence Biomedical Ltd. has received formal approval for its psilocybin product (NPX5) to be used in a Phase IIb clinical trial for psilocybin-assisted psychotherapy targeting Adjustment Disorder in cancer patients, positioning the company as a leader in the emerging psychedelics sector with strong cash reserves and a vertically integrated structure [1][2][4]. Financial Position - The company holds approximately $9.5 million in cash reserves and has no debt, enabling it to execute its strategic plans effectively [1][2]. Clinical Development - The Bellberry Human Research Ethics Committee has approved the use of PsyLabs' psilocybin product in the ongoing Phase IIb clinical trial, which will evaluate two therapeutic doses of psilocybin against a low-dose comparator [1][3][5]. - The Phase IIb study aims to enroll approximately 87 participants and is on track to deliver top-line results in 2026 [5]. Strategic Positioning - Psyence BioMed is evolving into a vertically integrated psychedelic enterprise with multiple assets across drug and clinical development, reinforcing its competitive positioning in the global psychedelics market [2][6]. - The approval of PsyLabs' psilocybin product is seen as a pivotal advancement in the company's clinical program and long-term strategy, enhancing supply-chain control and manufacturing excellence [4][6]. Company Overview - Psyence Biomedical Ltd. is a biopharmaceutical company focused on developing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, being the first of its kind listed on Nasdaq [7]. - The company is dedicated to an evidence-based approach in developing safe and effective psychedelic treatments for various mental health disorders [7]. PsyLabs Overview - PsyLabs is a federally licensed company specializing in the cultivation, extraction, and export of psilocybin and other psychedelic compounds, ensuring high standards of safety and traceability [9][10]. - The company has successfully exported psilocybin products to multiple countries and is expanding its product pipeline to include other next-generation psychedelics [9][10].